A RELIABLE MARKER OF ENDOTHELIAL CELL DYSFUNCTION: DOES IT EXIST?

British Journal of Haematology

Volumn 90, Issue 2, 1995, Pages 244-248

  BLANN, ANDREW D ^a   TABERNER, DAVID A ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b WITHINGTON HOSPITAL   (United Kingdom)

Author keywords

endothelial cells; plasminogen activator inhibitor; soluble E selectin; thrombomodulin; tissue plasminogen activator; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 5; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN; ENDOTHELIUM DERIVED RELAXING FACTOR; FIBRONECTIN; LAMININ; PLASMINOGEN ACTIVATOR INHIBITOR; PROSTACYCLIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; VITRONECTIN; VON WILLEBRAND FACTOR;

ENDOTHELIUM INJURY; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

CELL ADHESION MOLECULES; E-SELECTIN; ENDOTHELIUM, VASCULAR; HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 0029039751     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1995.tb05143.x     Document Type: Article

References (62)

1. Circulating intercellular adhesion molecule‐1 (ICAM‐1), E‐selectin and vascular cell adhesion molecule‐1 (VCAM‐1) in human malignancies
2. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the levels of plasma thrombomodulin, protein S, PAI‐1, tPA and vWf
3. von Willebrand factor and the endothelium in vascular disease
4. Increased levels of the soluble adhesion molecule E‐selectin in essential hypertension
5. Serum thrombomodulin: a novel marker of disease activity in systemic lupus erythematosus
6. Factor VIII complex and endothelial damage
7. Significance of raised plasma concentrations of tissue type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease
8. Biochemical properties of vascular endothelial cells
9. Biologically active thrombomodulin is synthesised by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis
10. The status of PAI‐1 as a risk factor for arterial and thrombotic disease: a review
11. Thrombomodulin
12. Exercise induced release of von Willebrand factor: evidence for hypoxic reperfusion microvascular injury in rheumatoid arthritis
13. Induction of angiotensin‐converting enzyme in human monocytes in culture
14. Soluble forms of vascular adhesion molecules E‐selectin, ICAM‐1 and VCAM‐1: pathological significance
15. Circulating adhesion molecules in disease
16. Are there markers of the blood‐vessel wall interaction and thrombus formation that can be used clinically
17. Endothelial cell biology and haemostasis
18. Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA
19. Changes in the factor VIII complex in diabetic ketoacidosis: evidence of endothelial cell damage
20. The hemostatic system and coronary heart disease
21. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction
22. Fibrinolytic pathways and the endothelium
23. Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross‐sectional study in Norsjo, Sweden
24. Up‐regulation of thromobomodulin in human umbilical vein endothelial cells in vitro
25. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells
26. Cell biology of endothelial cells
27. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction
28. Increased factor VIU/ von Willebrand factor antigen and von Willebrand factor activity in scleroderma and Raynaud's phenomenon
29. Prostacyclin production by cultured smooth muscle cells from atherosclerotic rabbit aorta
30. Tissue plasminogen activator
31. Localisation and production of plasminogen activator inhibitor‐1 in human healthy and atherosclerotic arteries
32. Effect of total body cold exposure on plasma concentrations of von Willebrand factor, endothelin‐1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon
33. Interrelationship between coagulant activity and tissue type plasminogen activator (t‐PA) system in acute ischaemic heart disease: possible role of the endothelium
34. Soluble E‐selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock
35. Haemostatic factors in coronary heart disease
36. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases
37. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease
38. Survival of 125‐iodine labelled factor VIII in normals and patients with classic hemophilia: observations on the heterogeneity of human factor VIII
39. Molecular cloning, expression and assembly of multimeric von Willebrand factor
40. Markers of endothelial cell pertubation and damage
41. Vessel wall interactions regulating thrombosis
42. Soluble forms of E‐selectin, ICAM‐1 and VCAM‐1 are present in the supernatants of cytokine‐activated endothelial cells
43. Cytokine mediated activation of vascular endothelium
44. von Willebrand factor is an acute phase reactant in man
45. A critical review of the relationship between impaired fibrinolysis and myocardial infarction
46. Endogenous tissue‐type plasminogen activator and risk of myocardial infarction
47. Prospective study of endogenous tissue plasminogen activator and risk of stroke
48. Levels of plasma thrombomodulin are increased in atheromatous arterial disease
49. Plasma thrombomodulin: new approach of endothelium damage
50. Vascular endothelial cells during hypoxia
51. Activation of coagulation and fibrinolysis in patients with arteriosclerosis: relation to localisation of vessel disease and risk factors
52. Is the increase in plasma von Willebrand factor concentrations in diabetes mellitus related to insulin levels
53. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue type plasminogen activator
54. Effects of acetyl salicyclic acid and cilostazol administration on serum thrombomodulin concentration in diabetic patients
55. Attenuation of thrombolysis by release of plasminogen activator inhibitor type‐1 from platelets
56. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation
57. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura
58. Tissue plasminogen activator, plasminogen activator inhibitor‐1 and von Willebrand factor in rheumatoid arthritis
59. Demonstration of a functionally active tPA‐like plasminogen activator in human platelets
60. A human chimera for von Willebrand disease following bone marrow transplantation
61. Tumour necrosis factor‐mediated release of plasminogen activator inhibitor 1 by human peritoneal mesothelial cells